BTG3 and metabolic dysfunction-associated steatotic liver disease: However, we found no difference in the risk of moderate-severe steatosis (scored of ≥2) and significant fibrosis (scored of ≥2) among NAFLD patients with ANA positivity compared with those with ANA negativity with the total ORs of 1.46 (95% CI 0.54 to 3.95) and 1.44 (95% CI 0.86 to 2.43), respectively (Figure 5).